MedTrace Logo

HbA1c as an Early Serologic Marker for the Hemodynamic Progression of Stage A Heart Failure

NCT04450576 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-11-16

No results posted yet for this study

Summary

In a retrospective community based cohort study from Pueblo County Colorado which has a higher population proportion of metabolic syndrome and diabetes mellitus, we hope to clarify and quantify an association of the AGE HBa1c elevation with the early subclinical hemodynamic changes of diabetic cardiomyopathy as measured by LAV, LVM, E/A ratio, E/e' ratio and BNP in patients with stage A heart failure.

Conditions

  • Heart Failure, Diastolic

Interventions

DIAGNOSTIC_TEST

Glycosylated hemoglobin

Glycosylated hemoglobin levels associated with correlative measures of diastolic cardiac function

Sponsors & Collaborators

  • Parkview Medical Center

    lead OTHER

Principal Investigators

  • Doug Duffee, MD · Parkview Medical Center

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-20
Primary Completion
2020-10-30
Completion
2020-12-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04450576 on ClinicalTrials.gov